Professional
Added to YB: 2026-07-09
Pitch date: 2026-07-04
VRTX [neutral]
Vertex Pharmaceuticals Incorporated
-5.36%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Market Cap
$132.5B
Pitch Price
$526.66
Price Target
N/A
Dividend
N/A
EV/EBITDA
23.15
P/E
30.97
EV/Sales
9.95
Sector
Biotechnology
Category
growth
Show full summary:
Andrew Hill Investment Advisors Portfolio Holding: Vertex Pharmaceuticals Incorporated
VRTX (holding update): Dominant Cystic Fibrosis franchise expanding into new rare-disease markets. Scaling two non-CF launches: Casgevy (gene editing) & Journavx (non-opioid acute pain). Backed by multiple regulatory approvals, positive Phase 3 data & multi-billion-dollar balance sheet.
Read full article (1 min)